# Ironwood Pharmaceuticals Inc. (IRWD) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Pharmaceuticals. Price $4.26, market value $704 million.

## Valuation
- **P/E (trailing): 5.4×** (5-yr avg 120.5×, 3-yr avg 232.7×). Ironwood Pharmaceuticals Inc. trades at 5.4× trailing earnings, well below its own five-year average of 120.5×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 2.8×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.00**. A PEG of 0.00 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 1.8×**. Each dollar of revenue is priced at 1.8×.
- **EV / EBITDA: 2.9×**. Enterprise value is 2.9× operating earnings before depreciation, the multiple that ignores how the company is financed; below 8× is inexpensive for most sectors.
- **Earnings yield: 18.5%**. The inverse of the P/E: 18.5% of the price is earned each year.

## Profitability
- **Operating margin: 60.1%**. 60.1% of revenue is left after running the business, an exceptional level.
- **Net margin: 8.1%**. 8.1% of each dollar of sales reaches the bottom line.
- **Return on equity: -9.2%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -66.5%**. Return on all capital, debt included, is -66.5%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: 32.7%**. Each dollar of assets produces 32.7% of profit.

## Growth
- **Revenue growth (1 yr): -15.7%** (3-yr -10.3%/yr, 5-yr -5.3%/yr). Revenue fell 15.7% over the last year, against -5.3% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 1400.0%** (3-yr -46.1%/yr, 5-yr -25.6%/yr). Earnings per share rose 1400.0%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): -22.6%/yr**. Free cash flow has compounded at -22.6% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Net debt / EBITDA: net cash**. Ironwood Pharmaceuticals Inc. holds more cash than debt.
- **Current ratio: 1.13** (quick 1.13). Current assets cover the next year's liabilities 1.13 times.
- **Altman Z-score: 1.38**. A Z-score of 1.38 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Ironwood Pharmaceuticals Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 287.3%** (YTD 26.4%, 3-mo 28.7%). The shares are up 287.3% over twelve months including dividends.
- **From 52-week high: -26.3%** (305.7% above the low). Trading 26% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 51**. An RSI of 51 is neutral.
- **Beta (1 yr): 2.00** (volatility 96%). Beta of 2.00 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=IRWD · Page: https://foliofundamentals.com/stocks/irwd

Not investment advice.